Trial Profile
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combo Tab Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg in Patients With Primary High Cholesterol and High Cardiovascular Risk Not Controlled With a Prior Statin Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Rosuvastatin
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms IN-CROSS
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 15 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 30 Apr 2009 Results have been published in the International Journal of Clinical Practice.
- 11 Nov 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.